GSK Summary


GSK (GlaxoSmithKline) is a science-led healthcare company. It has three businesses that research, develop, and manufacture pharmaceutical medicines, vaccines, and consumer healthcare products. The company develops vaccines against infectious diseases and provides a portfolio of medicines in respiratory, HIV, immuno-inflammation, and oncology. GSK combines science and consumer insights aiming to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy relief, digestive health, and vitamins, minerals, and supplements.

HQBrentford, GBMap
Employee Ratings
Overall CultureC+More


GSK is headquartered in
Brentford, United Kingdom

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Dec 2019)99,437(+4%)
Job Openings2,252
Website Visits (May 2021)2 m(+10%)
Revenue (FY, 2019)£33.8 B(+10%)
Share Price (Jun 2021)£14
Cybersecurity ratingBMore

Key People/Management at GSK

GSK Office Locations

GSK has offices in Brentford, Philadelphia, Boudouaou, San Fernando and in 86 other locations

GSK Financials and Metrics

GSK Revenue

GSK's revenue was reported to be £33.75 b in FY, 2019 which is a 9.5% increase from the previous period.


Revenue (Q3, 2020)£8.65 b
Gross profit (Q3, 2020)£5.76 b
Gross profit margin (Q3, 2020), %66.6%
Net income (Q3, 2020)£1.43 b
EBIT (Q3, 2020) £1.86 b
Market capitalization (11-Jun-2021)£70.61 b
Closing stock price(11-Jun-2021)£14.03
Cash (30-Sept-2020)£4.28 b
EV $94.58 b

GSK's current market capitalization is £70.6 b.

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Revenue27.9 b30.2 b30.8 b33.8 b
Revenue growth, %17%8%2%10%
Cost of goods sold9.3 b10.3 b10.2 b11.9 b
Gross profit18.6 b19.8 b20.6 b21.9 b
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Revenue7.4 b7.3 b7.8 b7.2 b7.3 b8.1 b7.7 b7.8 b9.4 b9.1 b7.6 b8.6 b
Cost of goods sold2.5 b2.6 b2.7 b2.4 b2.3 b2.6 b2.7 b2.6 b3.2 b3.2 b2.4 b2.9 b
Gross profit4.9 b4.7 b5.2 b4.8 b5 b5.5 b4.9 b5.2 b6.1 b5.9 b5.2 b5.8 b
Gross profit Margin, %66%64%66%67%68%67%64%66%65%65%68%67%
show all

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Cash4.9 b3.8 b3.9 b4.7 b
Accounts Receivable4.6 b4.7 b5.2 b5.5 b
Inventories5.1 b5.6 b5.5 b5.9 b
Current Assets16.7 b15.9 b16.9 b19.5 b
show all

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Net Income1.1 b2.2 b4 b5.3 b
Depreciation and Amortization1.6 b1.9 b1.9 b2.3 b
Accounts Receivable(188 m)(287 m)(984 m)(32 m)
Inventories70 m(461 m)51 m300 m
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Depreciation and Amortization326 m1.4 b2.1 b478 m673 m1.2 b1.2 b2 b2.5 b194 m(971 m)(330 m)
Cash From Operating Activities1.1 b2.2 b4 b863 m2.2 b4.3 b663 m2.1 b5.6 b965 m3.7 b4.6 b
Purchases of PP&E(260 m)(639 m)(1 b)(258 m)(541 m)(842 m)(222 m)(501 m)(785 m)(197 m)(420 m)(712 m)
Cash From Investing Activities(199 m)(646 m)(1.1 b)(371 m)(633 m)(1.1 b)(4 b)(4.5 b)(5 b)(58 m)2.8 b2.2 b
show all

Q3, 2020
EV/EBIT52.1 x
EV/CFO21.1 x
Debt/Equity1.4 x
Debt/Assets0.3 x
Financial Leverage3.9 x
P/E Ratio58.8 x
  • GSK Market Cap History

  • GSK Stock Price

Revenue Breakdown

GSK revenue breakdown by business segment: 26.7% from Consumer Healthcare, 21.2% from Vaccines and 52.1% from Global Pharmaceuticals

GSK revenue breakdown by geographic segment: 23.9% from Europe, 34.9% from International and 41.2% from US

GSK Operating Metrics

GSK's Vaccine Doses Delivered per Day was reported to be 2 m in FY, 2019.

FY, 2016FY, 2017FY, 2018FY, 2019
Volume of Medicines Produced2 b1.9 b2.3 b2.3 b
Manufacturing Facilities87
Partners1.5 k2 k

GSK Acquisitions / Subsidiaries

Company NameDateDeal Size
Sitari PharmaceuticalsSeptember 12, 2019
TESARODecember 04, 2018$5.1 b
GlycoVaxynFebruary 11, 2015$190 m
Okairos AGMay 29, 2013$325 m
Human Genome SciencesAugust 03, 2012$3 b
CellZomeMay 15, 2012£61 m
MaxiNutritionDecember 13, 2010£162 m
Nanjing MeiRui Pharma Co., Ltd.December 07, 2010$70 m
Laboratorios PhoenixJune 09, 2010$253 m
NovaMin TechnologyMay 24, 2010$135 m

Human Capital Metrics


GSK Hiring Categories

GSK Median Salaries

Source: 9 public H-1B filings from GSK

GSK Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

GSK Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

GSK Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

GSK Online and Social Media Presence

Twitter followers

223.55 k Twitter followers

6 Months

GSK has 223.55 k Twitter Followers. The number of followers has increased 0.18% month over month and increased 2.57% quarter over quarter.

GSK's Trends

Search term - GSK

Twitter Engagement Stats for @gsk

  • 12.45 k


  • 718


  • 223.55 k


  • 105

    Tweets last 30 days

  • 14.3

    Avg. likes per Tweet

  • 85.7%

    Tweets with engagement

GSK Technology StackBuildWith Logo

  • ads

    7 products used

    • DoubleClick.Net
    • Facebook Custom Audiences
    • Google Remarketing
      • JW Player Tracking
      • Rocket Fuel
      • travel audience
      • Twitter Ads
  • analytics

    14 products used

    • Adobe Marketing Cloud
    • Clicktools
    • Facebook Signal
      • Global Site Tag
      • Google Analytics
      • Google Analytics Enhanced Link Attribution
      • Google Conversion Tracking
      • Google Universal Analytics
      • New Relic
      • Omniture SiteCatalyst
      • Quantcast Measurement
      • Twitter Analytics
      • Twitter Conversion Tracking
      • Twitter Website Universal Tag
  • cdn

    10 products used

    • AJAX Libraries API
    • Akamai
    • Amazon S3
      • Azure Edge
      • Cloudinary
      • Content Delivery Network
      • Microsoft Azure Blob Storage
      • Microsoft Azure CDN
      • Twitter CDN
      • Yahoo Image CDN
  • cdns

    1 product used

    • Amazon CloudFront
Learn more on BuiltWith

GSK Company CultureCultureAndCompensation Logo

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

GSK News and Updates

Jun 14, 2021
iTeos stock jumps 60% after company announces deal with GSK
_3xOCqShares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy. GSK will make a $625 million upfront payment to iTeos, with an additional $1.4 billion in possible milestone payments available in the future. The immuno-oncology drug candidate is currently being tested in an open-label, Phase 1 clinical trial in patients with advanced solid tumors; as part of this deal, the companies plan to pair the iTeos drug with GSK's Jemperli in studies next year. (Jemperli was initially approved by the Food and Drug Administration as a treatment for endometrial cancer in April.) Shares of iTeos are down 40.8% so far this year, while the S&P 500 has gained 13.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.
Jun 14, 2021
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
_3xOCqGOSSELIES, Belgium and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial. With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints - TIGIT, CD96 and PVRIG.
Jun 09, 2021
Progentic, GSK to partner in lupus research
Progentic, a provider of diagnostic and digital technologies for proactive management of autoimmune diseases, has announced an 18-month collaborative research agreement with GlaxoSmithKline to evaluate novel measurement and management tools for systemic lupus erythematosus.
Jun 08, 2021
Progentec Announces Research Collaboration with GSK to Assess Proteomics and Digital Health Tools for Lupus (SLE) Care
Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus ("SLE" or "lupus").
May 30, 2021
: The FDA authorized the third antibody infusion therapy. Here’s why Vir and GSK say the U.S. still needs COVID-19 treatments
_3xOCqThere are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of medications that can be picked up at a local pharmacy.
May 29, 2021
Sanofi, GSK initiate Phase 3 clinical coronavirus vaccine trial
French and British pharmaceutical companies announced on Friday that they will initiate global phase 3 clinical efficacy studies of a coronavirus vaccine candidate, Anadolu Agency reports.

GSK Blogs

You may also be interested in Related companies

Ozon Pharm
Zhigulevsk, RU
Ozon Pharm is a pharmaceutical company that manufactures medicines.
View company
Bologna, IT
Alfasigma is a pharmaceutical company providing prescription and over-the-counter drugs.
View company
Aachen, DE
Grunenthal is a pharmaceutical company.
View company
Corbus Pharmaceuticals
Norwood, US
141  83increase
Corbus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.
View company
When was GSK founded?
GSK was founded in 2000.
Who are GSK key executives?
GSK's key executives are Faris El Refaie, Sridhar Venkatesh and Iain MacKay.
How many employees does GSK have?
GSK has 99,437 employees.
What is GSK revenue?
Latest GSK annual revenue is £33.75 b.
What is GSK revenue per employee?
Latest GSK revenue per employee is £339.45 k.
Who are GSK competitors?
Competitors of GSK include Johnson & Johnson, Roche and AstraZeneca.
Where is GSK headquarters?
GSK headquarters is located at 980 Great West Rd, Brentford.
Where are GSK offices?
GSK has offices in Brentford, Philadelphia, Boudouaou, San Fernando and 86 other locations
How many offices does GSK have?
GSK has 90 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu